Castle Biosciences (NASDAQ:CSTL) Insider Sells $107,418.96 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $32.67, for a total value of $107,418.96. Following the sale, the insider directly owned 35,565 shares of the company’s stock, valued at approximately $1,161,908.55. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL traded down $0.71 on Friday, reaching $33.79. 347,753 shares of the company were exchanged, compared to its average volume of 435,825. The company has a 50-day moving average of $34.35 and a 200-day moving average of $28.33. The company has a current ratio of 5.28, a quick ratio of 5.12 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -43.88 and a beta of 1.00. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.22. The company had revenue of $101.95 million for the quarter, compared to the consensus estimate of $92.76 million. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. Equities analysts forecast that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Castle Biosciences during the second quarter worth about $78,513,000. Jefferies Financial Group Inc. acquired a new stake in Castle Biosciences in the 2nd quarter worth about $15,440,000. AIGH Capital Management LLC purchased a new stake in Castle Biosciences in the 2nd quarter valued at about $13,001,000. Renaissance Technologies LLC grew its holdings in Castle Biosciences by 8.1% in the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after buying an additional 39,700 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Castle Biosciences in the 2nd quarter valued at about $7,912,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on CSTL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 29th. Mizuho initiated coverage on shares of Castle Biosciences in a research note on Thursday, October 29th. They set an “outperform” rating and a $60.00 price target on the stock. KeyCorp raised their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. BTIG Research lifted their price target on shares of Castle Biosciences from $44.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Finally, Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.